01—Abstract
Summary
Summary of the 8-K filed August 28, 2024. Cited figures are marked; the original filing is the authoritative source.
Neurocrine Biosciences, Inc. reported positive top-line data from its Phase 2 NBI-'568-SCZ2028 dose-finding study of NBI-'568 (NBI-1117568) in adults with schizophrenia experiencing an acute exacerbation or relapse.
The once-daily 20 mg dose met the primary endpoint, with a placebo-adjusted mean reduction of 7.5 points in PANSS total score at Week 6 (p=0.011, effect size 0.61) and an 18.2-point reduction from baseline. The 20 mg dose also showed statistically significant improvements on CGI-S and Marder Factor Scores for positive and negative symptoms. The 40 mg once-daily, 60 mg once-daily, and 30 mg twice-daily arms did not reach statistical significance on the primary endpoint versus placebo (p=0.282, p=0.189, and p=0.090, respectively).
The company stated that NBI-'568 was generally safe and well tolerated at all doses studied. Treatment discontinuation rates due to adverse events were 5.0%a across all NBI-'568 arms versus 4.3% for placebo, according to the slide presentation. The most common adverse events were somnolence, dizziness, and headache.
Gastrointestinal events, cardiovascular-related events, and extrapyramidal symptoms were reported at low frequency, and NBI-'568 was not associated with greater weight gain than placebo. Neurocrine expects to advance NBI-'568 into Phase 3 development in schizophrenia in early 2025. The filing describes NBI-'568 as the first investigational, oral, muscarinic M4 selective agonist in development for schizophrenia.
Neurocrine also noted a broader muscarinic portfolio, including NBI-1117567, NBI-1117569, and NBI-1117570, which it acquired from Nxera Pharma (formerly Sosei Heptares), and NBI-1076986, an internally developed M4 antagonist. The filing includes forward-looking statement cautions noting that top-line data may change after more comprehensive review.
02—Key points
Key Highlights
- The 20 mg once-daily dose met the primary endpoint, with a placebo-adjusted mean reduction of 7.5 points in PANSS total score at Week 6 (p=0.011; effect size 0.61).
- The 20 mg dose showed an 18.2-point PANSS total score reduction from baseline at Week 6.
- The 20 mg dose also showed statistically significant improvement on CGI-S (placebo-adjusted change of -0.7, p<0.001) and Marder Factor Scores for positive (p=0.004) and negative (p=0.028) symptoms.
- The 40 mg QD, 60 mg QD, and 30 mg BID arms did not reach statistical significance on the primary endpoint versus placebo (p=0.282, p=0.189, and p=0.090).
- Treatment discontinuation due to adverse events was 5.0% across NBI-'568 arms versus 4.3% for placebo; the most common adverse events were somnolence, dizziness, and headache.
- Neurocrine reported no greater weight gain than placebo, and GI and cardiovascular events were low in frequency.
- Neurocrine expects to begin Phase 3 development of NBI-'568 in schizophrenia in early 2025.
03—Questions
Frequently Asked Questions
What were the primary efficacy results for NBI-'568 in the Phase 2 study?
At Week 6, the 20 mg once-daily dose showed a PANSS total score reduction of 18.2 points from baseline, a placebo-adjusted mean reduction of 7.5 points (p=0.011), and an effect size of 0.61. The placebo group showed a mean reduction of 10.8 points.
Did any dose other than 20 mg meet the primary endpoint?
The filing reports that the 40 mg QD, 60 mg QD, and 30 mg BID arms did not show statistically significant differences from placebo on the PANSS total score at Week 6, with p-values of 0.282, 0.189, and 0.090, respectively.
How tolerable was NBI-'568 in the study?
Neurocrine stated that NBI-'568 was generally safe and well tolerated at all doses studied. Discontinuation due to adverse events was 5.0% across active arms versus 4.3% for placebo. The most common adverse events were somnolence, dizziness, and headache, and GI and cardiovascular events were low in frequency.
What are the next steps for NBI-'568?
Neurocrine expects to advance NBI-'568 into Phase 3 development in schizophrenia in early 2025. The company also stated it is evaluating additional indications for NBI-'568 and advancing follow-on compounds in its muscarinic agonist portfolio.
What makes NBI-'568 differentiated?
The filing describes NBI-'568 as the first investigational, oral, muscarinic M4 selective agonist in development for schizophrenia. It is described as an orthosteric agonist that does not depend on endogenous acetylcholine for efficacy and is dosed once daily with or without food.
04—Continue